title: Effects of Rosuvastatin and MiR-126 on Myocardial Injury Induced by Acute Myocardial Infarction in Rats: Role of Vascular Endothelial Growth Factor A (VEGF-A).
abstract: BACKGROUND The present study investigated the effects of VEGF-A targeted by miR-126 on myocardial injury after acute myocardial infarction (AMI) in rats, along with the contributions of rosuvastatin to the synergic effect. MATERIAL AND METHODS SD rats were obtained to construct AMI models by ligating their left anterior descending coronary arteries (LAD). We conducted echocardiography to check the 6 involved indexes: left ventricular ejection fractions (LVEF), fractional shortening (FS), left ventricular end-systolic volume (LVV), left ventricular end-diastolic volume (LVVd), cardiac output (CO), and heart rate (HR). Moreover, antibody sandwich enzyme-linked immunosorbent assay was carried out to determine MI markers: creatine kinase (CK), CK Isoenzyme (CK-MB), and Troponin I (cTn I). Dual-Luciferase Reporter Assay was performed to confirm the targeting of miR-126 and VEGF-A. MTT assay provided insight into the proliferation of myocardial fibroblasts. Finally, RT-RCR and Western blot were used for the detection of miR-126 and VEGF-A expressions in vivo and in vitro. RESULTS Luciferase activity assay showed that miR-126 transfection significantly decreased the relative luciferase activity in HEK293T cells when it was bound to normal 3' UTR of VEGF-A (P<0.05). In comparison to the control group, rats in the AMI model group had significantly lower LVEF, FS, and CO, and substantially higher LVVs, LVVd, HR, CK/U, CK-MB/U, and cTn-1/U (all P<0.05). Down-regulated miR-126 and up-regulated VEGF-A were also observed in MI models (P<0.05). CONCLUSIONS miR-126 and rosuvastatin have protective effects on AMI risk, and VEGF-A antagonizes effects on AMI is imposed by.
authors.affiliation: Fifth Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Ling
authors.initials: L
authors.lastname: Fei
authors.affiliation: Fifth Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Fifth Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Heping
authors.initials: H
authors.lastname: Niu
authors.affiliation: Fifth Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Chen
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Fifth Department of Cardiology, Cangzhou Central Hospital, Cangzhou, Hebei, China (mainland).
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Ma
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D052279:Creatine Kinase, MB Form / Q000378:metabolism; D004195:Disease Models, Animal; D057809:HEK293 Cells; D006335:Heart Injuries; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009206:Myocardium / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068718:Rosuvastatin Calcium / Q000494:pharmacology*; D013318:Stroke Volume / Q000502:physiology; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D015415:Biomarkers; C571458:MIRN126 microRNA, rat; D035683:MicroRNAs; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000068718:Rosuvastatin Calcium; D052279:Creatine Kinase, MB Form